NASDAQ: RGNX
Regenxbio Inc Stock

$7.30-0.02 (-0.27%)
Updated Feb 14, 2025
RGNX Price
$7.30
Fair Value Price
N/A
Market Cap
$361.68M
52 Week Low
$6.56
52 Week High
$28.80
P/E
-1.45x
P/B
1.2x
P/S
6.32x
PEG
N/A
Dividend Yield
N/A
Revenue
$84.33M
Earnings
-$238.81M
Gross Margin
54.4%
Operating Margin
-277.91%
Profit Margin
-283.2%
Debt to Equity
0.72
Operating Cash Flow
-$182M
Beta
1.27
Next Earnings
Feb 25, 2025
Ex-Dividend
N/A
Next Dividend
N/A

RGNX Overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine RGNX's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
RGNX
Ranked
#325 of 561

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important RGNX news, forecast changes, insider trades & much more!

RGNX News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RGNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RGNX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RGNX is good value based on its book value relative to its share price (1.2x), compared to the US Biotechnology industry average (4.77x)
P/B vs Industry Valuation
RGNX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RGNX due diligence checks available for Premium users.

Valuation

RGNX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.45x
Industry
-169.22x
Market
37.91x

RGNX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.2x
Industry
4.77x
RGNX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RGNX's financial health

Profit margin

Revenue
$24.2M
Net Income
-$59.6M
Profit Margin
-246.3%
RGNX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RGNX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$519.1M
Liabilities
$217.7M
Debt to equity
0.72
RGNX's short-term assets ($313.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RGNX's short-term assets ($313.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RGNX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RGNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$40.5M
Investing
$50.3M
Financing
-$10.9M
RGNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RGNX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
RGNXD$361.68M-0.27%-1.45x1.20x
TRMLD$354.64M+5.65%-34.58x1.10x
PRMEC$372.50M+9.44%-1.38x1.97x
CDXSC$350.74M+5.12%-4.95x4.78x
MBXD$347.88M+15.80%N/A1.28x

Regenxbio Stock FAQ

What is Regenxbio's quote symbol?

(NASDAQ: RGNX) Regenxbio trades on the NASDAQ under the ticker symbol RGNX. Regenxbio stock quotes can also be displayed as NASDAQ: RGNX.

If you're new to stock investing, here's how to buy Regenxbio stock.

What is the 52 week high and low for Regenxbio (NASDAQ: RGNX)?

(NASDAQ: RGNX) Regenxbio's 52-week high was $28.80, and its 52-week low was $6.56. It is currently -74.65% from its 52-week high and 11.28% from its 52-week low.

How much is Regenxbio stock worth today?

(NASDAQ: RGNX) Regenxbio currently has 49,545,071 outstanding shares. With Regenxbio stock trading at $7.30 per share, the total value of Regenxbio stock (market capitalization) is $361.68M.

Regenxbio stock was originally listed at a price of $30.45 in Sep 17, 2015. If you had invested in Regenxbio stock at $30.45, your return over the last 9 years would have been -76.03%, for an annualized return of -14.67% (not including any dividends or dividend reinvestments).

How much is Regenxbio's stock price per share?

(NASDAQ: RGNX) Regenxbio stock price per share is $7.30 today (as of Feb 14, 2025).

What is Regenxbio's Market Cap?

(NASDAQ: RGNX) Regenxbio's market cap is $361.68M, as of Feb 18, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Regenxbio's market cap is calculated by multiplying RGNX's current stock price of $7.30 by RGNX's total outstanding shares of 49,545,071.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.